BioSpace News Archive

Business

Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018

Egalet Corporation announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018.

July 25, 2018
·
5 min read
BioForest

Clinical Cardiology Publishes Study Demonstrating Simple Blood Test from Prevencio Accurately Detects Cardiovascular Disease

Multi-protein diagnostic test with 98 percent accuracy published in official journal of the American Society for Preventive Cardiology

July 25, 2018
·
4 min read
Drug Development

REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as monotherapy in patients whose tumors expressed PD-L1 (Combined Proportion Score (CPS) ≥20).

July 25, 2018
·
28 min read
Business

Hologic’s Global Access Initiative Increases Availability of Diagnostic Testing in Resource-Limited Countries

Program focuses on infectious disease assays - including HIV - for countries where critical testing is needed most

July 25, 2018
·
5 min read
Business

Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018

Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.

July 25, 2018
·
1 min read
Deals

Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs

First three programs to focus on Alzheimer’s disease and frontotemporal dementia

July 25, 2018
·
3 min read
BioMidwest

Probiotic with Digestive Enzymes Supplement Demonstrated to Reduce Cancer Chemotherapy Toxicity in Peer Reviewed Publication, according to Daily Body Restore, LLC

A probiotic with digestive enzymes supplement is effective at reversing chemotherapy- and antibiotic-induced damage to the gut microbiome.

July 25, 2018
·
3 min read
Biotech Bay

Addenbrooke’s Hospital is First in the UK to Treat Cancer Patients with Accuray Radixact® System

Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System

July 25, 2018
·
5 min read
Business

Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 1, 2018 to report its second quarter 2018 financial results and provide a corporate update.

July 25, 2018
·
1 min read
Drug Development

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Pharmaceutical Company Limited today announced that the global, randomized, Phase 3 ALTA-1L trial met its primary endpoint at the first pre-specified interim analysis, with ALUNBRIG®.

July 25, 2018
·
14 min read